NEW YORK (AP) - Shares of Juno Therapeutics plunged Friday after halting a midstage study on a potential leukemia treatment following two patient deaths.
The stock fell more than 26 percent in premarket trading about two hours before the market open.
The biotechnology company is developing a treatment for a type of leukemia.
Juno halts midstage drug study over deaths
Aucun commentaire:
Enregistrer un commentaire